Coloplast A/S develops and sells intimate healthcare products and services in Denmark, the United States, the United Kingdom, France, and internationally. The company operates through Chronic Care, Interventional Urology, Voice and Respiratory Care, and Wound & Skin Care segments. It provides ostomy care products, including SenSura Mio, which provides fit individual body shapes and optimal discretion for various types of ostomies; and SenSura Ostomy care solutions, as well as ostomy accessories under the Brava brand. The company also offers continence care products, such as Conveen Active urine bags; SpeediCath catheters that offer catheterization for both genders; and Peristeen, a transanal irrigation system. In addition, it provides wound care products comprising conforming dressing under the Biatain Silicone brand and hydrocolloid dressing under the Comfeel brand; and skin care products that include cleansers, moisturizers, skin protectants, antifungal products, hand cleanser, and odor control products, as well as InterDry, a skin fold management solution. Further, the company develops, produces, and markets products for the surgical treatment of urological and gynecological disorders, such as urinary stone diseases, benign prostate hyperplasia, voiding dysfunctions, erectile dysfunction, and urinary incontinence. Additionally, it offers voice and respiratory products, including medical devices for neck stoma under the Provox brand; and products for tracheostoma under the TRACOE brand. The company was founded in 1954 and is headquartered in Humlebæk, Denmark.

History

Coloplast was founded in 1957 by Aage Louis-Hansen. His son Niels Peter Louis-Hansen owns 20% of the company and is deputy chairman. It employs more than 12,000 people and operates around the world, with sales activities in 53 countries and production in Denmark, Hungary, France, China and the US. It has its global headquarters in Humlebæk, Denmark. Its United States operations and North American headquarters are based in Minneapolis, Minnesota. The company manufactures and supplies products to hospitals and institutions, as well as wholesalers and retailers. In selected markets, Coloplast is a direct supplier to consumers.

The company had revenues of DKK 18.554 billion in 2020/2021. Europe constitutes the biggest market with 63% of sales, while 22% of sales are in North America and 15% in the rest of the world. Coloplast is listed on the Danish Stock Exchange, and has for a number of years been represented among the 20 most traded shares in the country.In 2016, Coloplast was listed as the 22nd most innovative company in the world by Forbes Forbes. In 2015, Coloplast was listed as the 33rd most innovative company in the world by Forbes Magazine. The company has been featured in The Star Tribune's annual list of top employers in Minnesota.In November 2021, Coloplast announces the acquisition for 2.5 billion dollars of Atos Medical, specialized in laryngectomy, which belonged to PAI Partners.

Mission

To make life easier for people with intimate healthcare needs.

Vision

To be the first choice for healthcare professionals and people with intimate healthcare needs.

Key Team

Mr. Nicolai Buhl Andersen (Exec. VP of Innovation)

Mr. Paul Marcun (Exec. VP of Growth)

Ellen Bjurgert (VP of Investor Relations)

Mr. Thomas Barfod (Sr. Controller & Employees Representative Director)

Dorthe Ronnau (Sr. VP of People & Culture)

Dennis Kaysen (Director of Corp. Communications)

Mr. Alain Morvan (Sr. VP of Sales Europe)

Recognition and Awards

We are proud to have been recognised for many prestigious awards over the years, ranging from industry awards to government institutions and the royal court.